Adenoid Cystic Carcinoma of Salivary Glands: A Ten-Year Review and an Assessment of the Current Management, Surgery, Radiotherapy, and Chemotherapy

International Journal of Otolaryngology, Год журнала: 2023, Номер 2023, С. 1 - 16

Опубликована: Апрель 29, 2023

Adenoid cystic carcinoma (ACC) is a rare cancer that arises from the salivary glands and other sites in body, such as lung breast. Although tumor accounts for 10% of all gland malignancies, it only 1% head neck malignancies. It can affect both major minor glands; here, called adenoid or SACC, with slight predilection to latter, commonly manifests between 6th 7th decades life. The disease also shows female predilection, reported male ratio 3 : 2. Lesions SACC are often insidious slow-growing, symptoms pain altered sensation frequently associated advanced stages disease. Salivary characterized by perineural invasion (PNI), distinctive feature potentially plays significant role tumor’s relapse recurrence, which approximately 50%. not prevalent, its etiopathogenesis poorly understood, although several genetic patterns biomarkers have been linked initiation and/or progression. discovery these mutations has encouraged clinical studies use therapeutic agents target specific receptors on cells prevent further proliferation metastasis Diagnosis challenging requires combination examination, imaging, histopathology. Management primarily surgical excision, while radiotherapy shown be effective improving local control cases microscopic residual However, treatment recurrent metastatic tumors without chemotherapy so far limited success. aim this thesis provide an update literature particular focus latest management approaches future trends.

Язык: Английский

---

Adenoid Cystic Carcinoma of the Minor Salivary Glands: A Systematic Review and Meta-Analysis of Clinical Characteristics and Management Strategies

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(1), С. 267 - 267

Опубликована: Янв. 3, 2024

Background: Intraoral adenoid cystic carcinoma (ACC) arising from minor salivary glands (MSG) is a rare malignancy associated with delayed diagnosis and unfavorable outcomes. This study aimed to comprehensively review ACC of MSGs, focusing on clinical characteristics, imaging modalities, treatment approaches, long-term Methods: A systematic search was conducted in PubMed, Web Science, MEDLINE databases identify relevant articles reporting cases MSGs between January 1997 March 2023. The registered PROSPERO (ID: CRD42023449478). total 10 studies that met the inclusion criteria were selected for critical review. In total, 902 patients diagnosed an age range 44.3 63 years, average 56.6 years. female male ratio ranges 1:1 2.4:1. Regarding primary site ACC, palate most common location, accounting 30.5% 83.3%, followed by buccal mucosa, floor mouth, lip retromolar area. For histology, solid mass pattern prevalent, seen 95.2% patients, cribriform pattern. surgery approach, applied 76.3% cases, combination radiotherapy used 29.0% cases. smaller fraction, 3.2%, received surgery, chemotherapy, radiotherapy, 8.3% underwent alone. Local recurrence rates varied 1% 28.5%, distant metastasis occurred 18.2% 33.3% predominantly lymph nodes (14.5%). An analysis overall survival across various stages patient numbers indicated 5-year rate 68.0%. findings this provide valuable insights physicians making decisions emphasize need ongoing research collaborative efforts improve management outcomes challenging disease. Conclusion: multifaceted condition typically manifesting as asymptomatic enlargement ulceration. disease marked distinct histopathological patterns perineural invasion (PNI). Recognizing these distinctive aspects key shaping plan, which can surgical procedures radiation therapy, evolving targeted treatments. Continuous remain progress condition.

Язык: Английский

---

Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review)

Oncology Letters, Год журнала: 2025, Номер 29(3)

Опубликована: Янв. 22, 2025

Adenoid cystic carcinoma (ACC) of the salivary glands is second most common type gland cancer, and characterized by a poor prognosis an unclear pathology. The incidence ACC rare, as it accounts for 10-15% all tumors affects mainly patients aged between 50 60 years. annual rate estimated to be ~4.5 cases per 100,000 individuals. Due its rarity use contaminated cell lines in previous investigations, precise etiological factors underlying remain poorly understood. Current treatment modalities, typically involving surgery with or without postoperative radiotherapy, often prove unsatisfactory due potential local recurrence delayed distant metastases, which may manifest 3-5 years after constitute primary failure existing therapeutic approaches. indolent growth pattern, along perineural perivascular invasion, potentially responsible onset metastases. No effective systemic therapy has been established so far. Therefore, management represents significant challenge. Exploring molecular characteristics ACC, including reasons behind propensity invasion correlation immune system, offers promising strategies managing could open up novel pathways future interventions. Currently, immunotherapy shown limited effectiveness. While exact mechanism lack response remains unknown, low levels tumor-infiltrating lymphocytes these contribute this resistance. identifying targets enhance against tumor cells essential. present review provides update on clinical studies explores that ACC.

Язык: Английский

---

Apolipoprotein D is crucial for promoting perineural invasion in salivary adenoid cystic carcinoma

British Journal of Cancer, Год журнала: 2025, Номер unknown

Опубликована: Фев. 17, 2025

Язык: Английский

---

Salivary glands adenoid cystic carcinoma: a molecular profile update and potential implications

Frontiers in Oncology, Год журнала: 2023, Номер 13

Опубликована: Июль 5, 2023

Adenoid cystic carcinoma (ACC) is an aggressive tumor with a high propensity for distant metastasis and perineural invasion. This more commonly found in regions of the head neck, mainly salivary glands. In general, primary treatment modality ACC surgical resection and, some cases, postoperative radiotherapy. However, no effective systemic available patients advanced disease. Furthermore, this type characterized by recurrent molecular alterations, especially rearrangements involving MYB, MYBL1 , NFIB genes. addition, they also reported copy number alterations (CNAs) that impact One them C-KIT mutations affect signaling pathways such as NOTCH, PI3KCA, PTEN, well chromatin remodeling The identification new targets enables development specific therapies. Despite ongoing investigations into immunotherapy, tyrosine kinase inhibitors, anti-angiogenics, therapy approved FDA ACC. review, we report genetic cytogenetic findings on neck ACC, highlighting possible therapeutic interventions.

Язык: Английский

---

Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review

Diagnostic Pathology, Год журнала: 2023, Номер 18(1)

Опубликована: Май 17, 2023

Pulmonary adenoid cystic carcinoma (PACC) is an exceptionally rare salivary gland-type malignant neoplasm. Because of its clinical manifestations, imaging features are not different from other types non-small cell lung cancer, which a diagnostic challenge for most doctors.A review the literature shows that high amounts immunohistochemical (IHC) markers, such as CK7, CD117, P63, SMA, CK5/6, and S-100 helpful PACC diagnosis. Surgical resection main treatment PACC, but options advanced patients limited research molecular targeted drugs ongoing in cases eligible surgery. Currently, on therapy mainly focuses exploration v-myb avian myeloblastosis virus oncogene homolog (MYB) downstream target genes. In addition, median tumor mutation burden PD-1/PD-L1 were lower may indicate poor efficacy immunotherapy patients. This pathologic features, characteristics, diagnosis, prognosis to establish comprehensive understanding PACC.

Язык: Английский

---

Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis

Clinical and Translational Radiation Oncology, Год журнала: 2025, Номер unknown, С. 100945 - 100945

Опубликована: Март 1, 2025

Язык: Английский

---

Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma

Oral Oncology, Год журнала: 2023, Номер 148, С. 106635 - 106635

Опубликована: Ноя. 21, 2023

Adenoid cystic carcinoma (ACC) is a rare type of cancer that typically arises from glandular tissues, most commonly in the salivary glands. Although relatively rare, it represents serious clinical issue as management disease highly complex being only therapeutic options represented by invasive surgery and/or radiotherapy. In present study, we have explored potential galectin-3 binding protein (LGALS3BP) novel target for antibody-drug conjugate (ADC) therapy ACC.

Язык: Английский

---

Adenoid cystic carcinoma of distal trachea: A case report

Clinical Case Reports, Год журнала: 2024, Номер 12(2)

Опубликована: Фев. 1, 2024

This case report highlights the rarity of distal tracheal adenoid cystic carcinoma and emphasizes importance considering it as a differential diagnosis in patients presenting with sustained dyspnea. Early multidisciplinary approach involving thoracic surgeons, radiation oncologists, medical oncologists are crucial for optimal treatment planning patient outcomes. Further research is warranted to better understand pathogenesis, molecular characteristics, management strategies this rare malignancy.

Язык: Английский

---

A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma

EJNMMI Research, Год журнала: 2022, Номер 12(1)

Опубликована: Авг. 19, 2022

This pilot study was designed to evaluate the diagnostic value of 68 Ga-PSMA-617 and 18F-FDG PET/CT in adenoid cystic carcinoma (ACC) assess safety therapeutic response PSMA radioligand therapy (RLT) ACC patients.Thirty patients pathologically diagnosed with were recruited into cohort. Each patient underwent within 1 week. The number SUVmax PET-positive lesions recorded compared. Four accepted RLT using 177Lu-EB-PSMA-617, a dosage approximately 1.85 GBq (50 mCi) per cycle for up 3 cycles.Compared 18F-FDG, revealed more extrapulmonary tumors (157 vs. 141, P = 0.016) higher (8.8 ± 3.6 6.4 4.2, 0.027). However, less pulmonary (202 301, < 0.001) lower (3.1 3.0 4.2 3.9, than 18F-FDG. combination can detect 469 lesions, which superior each alone (469 359 442, 0.001). Two achieved remarkable after RLT, while other two showed reduced tumor uptake recurrent foci, lung liver metastases, whereas increased bone metastases.68 is valuable imaging modality detection combining will achieve efficiency. may be promising treatment worth further investigation.Diagnosis Adenoid Cystic Carcinoma on PET-CT Therapy With 177Lu-EB-PSMA-617 (NCT04801264, Registered 16 March 2021, retrospectively registered). URL registry: https://clinicaltrials.gov/ct2/show/NCT04801264 .

Язык: Английский

---